Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced that two analyses from the CLEAR Outcomes trial were accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, November 7-10, 2025.

An oral presentation titled “Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial” is scheduled for November 9, 2025, 9:45–11:00 AM CST, presented by Carolina Pires Zingano, MD of Cleveland Clinic. A poster, “Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial”, will appear in the moderated digital poster session VM.MDP.07 on November 9, 2025, 11:50 AM–1:05 PM CST, presented by Bernardo Frison Spiazzi, MD of Cleveland Clinic.

Company leadership highlighted that CLEAR Outcomes continues to yield clinically relevant insights on statin intolerance and treatment options for patients with elevated LDL-C.

News Market Reaction

+7.01%

15 alerts

+7.01% News Effect

+8.4% Peak in 22 hr 42 min

+$47M Valuation Impact

$722M Market Cap

0.5x Rel. Volume

On the day this news was published, ESPR gained 7.01%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.4% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $47M to the company's valuation, bringing the market cap to $722M at that time.

Data tracked by StockTitan Argus on the day of publication.

ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025.

Oral Presentation
Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial
November 9, 2025, 9:45 – 11:00 AM CST
Presenter: Carolina Pires Zingano, MD (Cleveland Clinic)

Poster Presentation
Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial
Moderated Digital Poster Session, VM.MDP.07 Top Clinical and Translational Abstracts in Vascular Medicine: 
November 9, 2025, 11:50 AM – 1:05 PM CST
Presenter: Bernardo Frison Spiazzi, MD (Cleveland Clinic)

“The landmark CLEAR Outcomes trial continues to provide clinically meaningful insights that highlight the challenges of statin intolerance and reinforce the importance of expanding treatment options for patients at risk of cardiovascular events due to elevated LDL-C,” said Sheldon Koenig, president and CEO of Esperion.

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion present CLEAR Outcomes analyses at AHA Scientific Sessions 2025 (ESPR)?

Esperion has presentations scheduled for November 9, 2025 during AHA Scientific Sessions 2025 in New Orleans.

What is the title and timing of Esperion's oral presentation at AHA 2025 (ESPR)?

Oral presentation “Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events” is on November 9, 2025, 9:45–11:00 AM CST.

Who will present the oral CLEAR Outcomes analysis for Esperion at AHA 2025 (ESPR)?

The oral presentation will be delivered by Carolina Pires Zingano, MD from Cleveland Clinic.

What is Esperion's poster presentation at AHA 2025 and when is it scheduled (ESPR)?

Poster “Effects of Bempedoic Acid on Venous Thromboembolism” is in moderated digital poster session VM.MDP.07 on November 9, 2025, 11:50 AM–1:05 PM CST.

Who presents Esperion's poster on bempedoic acid at AHA 2025 (ESPR)?

The poster will be presented by Bernardo Frison Spiazzi, MD from Cleveland Clinic.

What clinical topics will Esperion highlight from CLEAR Outcomes at AHA 2025 (ESPR)?

The presentations focus on bempedoic acid effects on LDL cholesterol, cardiovascular events, and venous thromboembolism based on CLEAR Outcomes analyses.